Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling

Brendan J. Quinn, Matthew Dallos, Hiroshi Kitagawa, Ajaikumar B. Kunnumakkara, Regan M. Memmott, M. Christine Hollander, Joell Gills, Phillip A. Dennis

Research output: Contribution to journalArticle

Abstract

Metformin is the most commonly prescribed drug for type II diabetes and is associated with decreased cancer risk. Previously, we showed that metformin prevented tobacco carcinogen (NNK)-induced lung tumorigenesis in a non-diabetic mouse model, which was associated with decreased IGF-I/insulin receptor signaling but not activation of AMPK in lung tissues, as well as decreased circulating levels of IGF-I and insulin. Here, we used liver IGF-I-deficient (LID) mice to determine the importance of IGF-I in NNK-induced lung tumorigenesis and chemoprevention by metformin. LID mice had decreased lung tumor multiplicity and burden compared with wild-type (WT) mice. Metformin further decreased lung tumorigenesis in LID mice without affecting IGF-I levels, suggesting that metformin can act through IGF-I-independent mechanisms. In lung tissues, metformin decreased phosphorylation of multiple receptor tyrosine kinases (RTK) as well as levels of GTP-bound Ras independently of AMPK. Metformin also diminished plasma levels of several cognate ligands for these RTKs. Tissue distribution studies using [14C]-metformin showed that uptake of metformin was high in liver but four-fold lower in lungs, suggesting that the suppression of RTK activation by metformin occurs predominantly via systemic, indirect effects. Systemic inhibition of circulating growth factors and local RTK signaling are new AMPK-independent mechanisms of action of metformin that could underlie its ability to prevent tobacco carcinogen-induced lung tumorigenesis.

Original languageEnglish (US)
Pages (from-to)801-810
Number of pages10
JournalCancer Prevention Research
Volume6
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

IGF Type 1 Receptor
Metformin
Protein-Tyrosine Kinases
Carcinogenesis
Insulin-Like Growth Factor I
Lung
AMP-Activated Protein Kinases
Liver
Receptor Protein-Tyrosine Kinases
Carcinogens
Tobacco
Growth Factor Receptors
Insulin Receptor
Chemoprevention
Tissue Distribution
Guanosine Triphosphate
Tumor Burden
Type 2 Diabetes Mellitus
Phosphorylation
Insulin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. / Quinn, Brendan J.; Dallos, Matthew; Kitagawa, Hiroshi; Kunnumakkara, Ajaikumar B.; Memmott, Regan M.; Hollander, M. Christine; Gills, Joell; Dennis, Phillip A.

In: Cancer Prevention Research, Vol. 6, No. 8, 08.2013, p. 801-810.

Research output: Contribution to journalArticle

Quinn, Brendan J. ; Dallos, Matthew ; Kitagawa, Hiroshi ; Kunnumakkara, Ajaikumar B. ; Memmott, Regan M. ; Hollander, M. Christine ; Gills, Joell ; Dennis, Phillip A. / Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. In: Cancer Prevention Research. 2013 ; Vol. 6, No. 8. pp. 801-810.
@article{3052e6166c6546f0899ab0aed4b2b410,
title = "Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling",
abstract = "Metformin is the most commonly prescribed drug for type II diabetes and is associated with decreased cancer risk. Previously, we showed that metformin prevented tobacco carcinogen (NNK)-induced lung tumorigenesis in a non-diabetic mouse model, which was associated with decreased IGF-I/insulin receptor signaling but not activation of AMPK in lung tissues, as well as decreased circulating levels of IGF-I and insulin. Here, we used liver IGF-I-deficient (LID) mice to determine the importance of IGF-I in NNK-induced lung tumorigenesis and chemoprevention by metformin. LID mice had decreased lung tumor multiplicity and burden compared with wild-type (WT) mice. Metformin further decreased lung tumorigenesis in LID mice without affecting IGF-I levels, suggesting that metformin can act through IGF-I-independent mechanisms. In lung tissues, metformin decreased phosphorylation of multiple receptor tyrosine kinases (RTK) as well as levels of GTP-bound Ras independently of AMPK. Metformin also diminished plasma levels of several cognate ligands for these RTKs. Tissue distribution studies using [14C]-metformin showed that uptake of metformin was high in liver but four-fold lower in lungs, suggesting that the suppression of RTK activation by metformin occurs predominantly via systemic, indirect effects. Systemic inhibition of circulating growth factors and local RTK signaling are new AMPK-independent mechanisms of action of metformin that could underlie its ability to prevent tobacco carcinogen-induced lung tumorigenesis.",
author = "Quinn, {Brendan J.} and Matthew Dallos and Hiroshi Kitagawa and Kunnumakkara, {Ajaikumar B.} and Memmott, {Regan M.} and Hollander, {M. Christine} and Joell Gills and Dennis, {Phillip A.}",
year = "2013",
month = "8",
doi = "10.1158/1940-6207.CAPR-13-0058-T",
language = "English (US)",
volume = "6",
pages = "801--810",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling

AU - Quinn, Brendan J.

AU - Dallos, Matthew

AU - Kitagawa, Hiroshi

AU - Kunnumakkara, Ajaikumar B.

AU - Memmott, Regan M.

AU - Hollander, M. Christine

AU - Gills, Joell

AU - Dennis, Phillip A.

PY - 2013/8

Y1 - 2013/8

N2 - Metformin is the most commonly prescribed drug for type II diabetes and is associated with decreased cancer risk. Previously, we showed that metformin prevented tobacco carcinogen (NNK)-induced lung tumorigenesis in a non-diabetic mouse model, which was associated with decreased IGF-I/insulin receptor signaling but not activation of AMPK in lung tissues, as well as decreased circulating levels of IGF-I and insulin. Here, we used liver IGF-I-deficient (LID) mice to determine the importance of IGF-I in NNK-induced lung tumorigenesis and chemoprevention by metformin. LID mice had decreased lung tumor multiplicity and burden compared with wild-type (WT) mice. Metformin further decreased lung tumorigenesis in LID mice without affecting IGF-I levels, suggesting that metformin can act through IGF-I-independent mechanisms. In lung tissues, metformin decreased phosphorylation of multiple receptor tyrosine kinases (RTK) as well as levels of GTP-bound Ras independently of AMPK. Metformin also diminished plasma levels of several cognate ligands for these RTKs. Tissue distribution studies using [14C]-metformin showed that uptake of metformin was high in liver but four-fold lower in lungs, suggesting that the suppression of RTK activation by metformin occurs predominantly via systemic, indirect effects. Systemic inhibition of circulating growth factors and local RTK signaling are new AMPK-independent mechanisms of action of metformin that could underlie its ability to prevent tobacco carcinogen-induced lung tumorigenesis.

AB - Metformin is the most commonly prescribed drug for type II diabetes and is associated with decreased cancer risk. Previously, we showed that metformin prevented tobacco carcinogen (NNK)-induced lung tumorigenesis in a non-diabetic mouse model, which was associated with decreased IGF-I/insulin receptor signaling but not activation of AMPK in lung tissues, as well as decreased circulating levels of IGF-I and insulin. Here, we used liver IGF-I-deficient (LID) mice to determine the importance of IGF-I in NNK-induced lung tumorigenesis and chemoprevention by metformin. LID mice had decreased lung tumor multiplicity and burden compared with wild-type (WT) mice. Metformin further decreased lung tumorigenesis in LID mice without affecting IGF-I levels, suggesting that metformin can act through IGF-I-independent mechanisms. In lung tissues, metformin decreased phosphorylation of multiple receptor tyrosine kinases (RTK) as well as levels of GTP-bound Ras independently of AMPK. Metformin also diminished plasma levels of several cognate ligands for these RTKs. Tissue distribution studies using [14C]-metformin showed that uptake of metformin was high in liver but four-fold lower in lungs, suggesting that the suppression of RTK activation by metformin occurs predominantly via systemic, indirect effects. Systemic inhibition of circulating growth factors and local RTK signaling are new AMPK-independent mechanisms of action of metformin that could underlie its ability to prevent tobacco carcinogen-induced lung tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=84883764605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883764605&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-13-0058-T

DO - 10.1158/1940-6207.CAPR-13-0058-T

M3 - Article

C2 - 23771523

AN - SCOPUS:84883764605

VL - 6

SP - 801

EP - 810

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 8

ER -